Nutritional Intervention Trial to Improve Liver Function Related Blood Biomarkers in Heavyweight Athletes

Nutritional Approaches to Improving Liver Function Biomarkers in Heavyweight Athletes - Nutritional Intervention Trial in Heavyweight Athletes

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000061121

Enrollment

Registered

2026-04-01

Start date

2026-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obesity Liver dysfunction

Interventions

Participants will be selected based on screening blood tests, specifically those with AST and ALT levels of &gt

30 mg/dL and not markedly exceeding 40 mg/dL. Individuals who are found to have fatty liver on MRI and are deemed to require medical treatment will be excluded. The athletes who meet the criteria will

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Individuals will be selected based on screening blood tests conducted in heavyweight athletes, specifically those with AST and ALT levels of >30 mg/dL and not markedly exceeding 40 mg/dL.

Exclusion criteria

Exclusion criteria: Participants who are found to have fatty liver on MRI and are judged by a physician to require medical treatment will be excluded from the study.

Design outcomes

Primary

Measure	Time frame
Degree of improvement in serum ALT levels after the 3-month nutritional intervention	—

Secondary

Measure	Time frame
This study will collect body composition data, energy and nutrient intake, and a comprehensive panel of blood biomarkers, including hemoglobin, hematocrit, MCV, MCH, MCHC, white blood cell count, platelet count, AST, ALT, GTP, total protein, albumin, aldolase, total bilirubin, uric acid, creatinine, LDH, ALP, CK, total cholesterol, triglycerides, HDL-cholesterol, LDL-cholesterol, total bile acids, blood glucose, HbA1c, and the FIB-4 index. Salivary biomarkers such as cortisol, secretory IgA, and IL-6 will also be assessed. In addition, abdominal ultrasound parameters (liver stiffness, attenuation imaging value, and attenuation coefficient) and abdominal MRI parameters (proton density fat fraction, visceral fat area, and subcutaneous fat area) will be evaluated. Training status, psychological status, and sleep status will likewise be recorded.	—

Measure

Time frame

This study will collect body composition data, energy and nutrient intake, and a comprehensive panel of blood biomarkers, including hemoglobin, hematocrit, MCV, MCH, MCHC, white blood cell count, platelet count, AST, ALT, GTP, total protein, albumin, aldolase, total bilirubin, uric acid, creatinine, LDH, ALP, CK, total cholesterol, triglycerides, HDL-cholesterol, LDL-cholesterol, total bile acids, blood glucose, HbA1c, and the FIB-4 index. Salivary biomarkers such as cortisol, secretory IgA, and IL-6 will also be assessed. In addition, abdominal ultrasound parameters (liver stiffness, attenuation imaging value, and attenuation coefficient) and abdominal MRI parameters (proton density fat fraction, visceral fat area, and subcutaneous fat area) will be evaluated. Training status, psychological status, and sleep status will likewise be recorded.

—

Countries

Japan

Contacts

Public ContactMEGUMI MATSUMOTO

College of Humanities and Sciences,Nihon University Department of Physical Education

matsumoto.megumi@nihon-u.ac.jp0353179717

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026